We couldn’t be more excited to welcome Jason Kelly to Compound as a Venture Partner.
We initially connected with Jason on X when we were some of the few folks talking about autonomous science. In the time since we first chatted, Jason and his team at Ginkgo have built the largest autonomous lab in the country for discovery biology. This enables both faster feedback loops for everyone in our industry and eventually the ability to enable a future where everyone does biotech.
Biotech futures is another core ideological connection we have with Jason. From running an Idea Factory event with him to trading notes on the future of consumer biotech and wearables, we realized there were endless topics for us to discuss, debate, and ideate on. These are the types of traits we admire and look for on our team at Compound, and through these conversations it became clearer to us that Jason would be a force multiplier to everything we do and especially for the founders we work with.
What we admired about Jason even before meeting is how he made Ginkgo into the Schelling Point company of synthetic biology. And Jason has the prescient ability to predict a new category and become the de facto example of its promise.
99.9% of Jason’s time is continuing to build Ginkgo but as a Venture Partner with us, we couldn’t be more enthused to work with Jason given so much overlap in our startup ideologies, scope, and beliefs of the future.
